Clinical Trial Update: AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial is evaluating AZD0305 as a monotherapy or in combination with anticancer agents for relapsed/refractory multiple myeloma, with recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• AZD0305 (AZD0305)

Snippet

Sponsor: AstraZeneca | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: RECRUITING